Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study
Abel Santos Carreira(University Health Network), Jonas Mattsson(University Health Network), Jeffrey H. Lipton(University of Toronto), María Queralt Salas(Princess Margaret Cancer Centre), Rajat Kumar(Princess Margaret Cancer Centre), Armin Gerbitz(University Health Network), Igor Novitzky‐Basso(University Health Network), Arjun Law(Princess Margaret Cancer Centre), Ivan Pašić(University Health Network), Auro Viswabandya(Princess Margaret Cancer Centre), Fotios V. Michelis(Princess Margaret Cancer Centre), Shahid Husain(University Health Network), Dennis Kim(Princess Margaret Cancer Centre), Wilson Lam(Princess Margaret Cancer Centre), Mats Remberger(Uppsala University Hospital)
Cited by 37
Related Papers
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
|Leukemia|2008|354
Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort Study
|Clinical Infectious Diseases|2012|299
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
|Oncotarget|2017|187
Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies
|Biology of Blood and Marrow Transplantation|2018|92